Evidence map›Paper›PMID 32789000›Full record

ArticleF1000Research2019

Variable expression and silencing of CRISPR-Cas9 targeted transgenes identifies the

Jamie R Bhagwan, Emma Collins, Diogo Mosqueira, Mine Bakar, Benjamin B Johnson, Alexander Thompson, James G W Smith, Chris Denning

Open access · goldAbstract read
In one paragraph

Article in F1000Research, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers.

0numbers the graph read from it
0cells of the map it votes in
30citing papers in PubMed
1.8field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

30 citing papers in PubMed, 42 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Article
  5. Article
  6. Reversing transgene silencing via targeted chromatin editing.bioRxiv : the preprint server for biology · 2025
    Article
  7. Article
  8. Article
  9. Accelerating Diverse Cell-Based Therapies Through Scalable Design.Annual review of chemical and biomolecular engineering · 2024
    Review
  10. Article
  11. Targeted Gene Insertion: The Cutting Edge of CRISPR Drug Development with Hemophilia as a Highlight.BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy · 2024
    Review
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. A primer onFrontiers in medicine · 2023
    Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 1 country.

Jamie R BhagwanDepartment of Stem Cells, Tissue Engineering and Modelling, Centre for Biomolecular Sciences, University of Nottingham, Nottingham, NG7 2RD, UK.ORCID 0000-0002-3333-730X
Emma CollinsDepartment of Stem Cells, Tissue Engineering and Modelling, Centre for Biomolecular Sciences, University of Nottingham, Nottingham, NG7 2RD, UK.
Diogo MosqueiraDepartment of Stem Cells, Tissue Engineering and Modelling, Centre for Biomolecular Sciences, University of Nottingham, Nottingham, NG7 2RD, UK.
Mine BakarDepartment of Stem Cells, Tissue Engineering and Modelling, Centre for Biomolecular Sciences, University of Nottingham, Nottingham, NG7 2RD, UK.
Benjamin B JohnsonDepartment of Stem Cells, Tissue Engineering and Modelling, Centre for Biomolecular Sciences, University of Nottingham, Nottingham, NG7 2RD, UK.
Alexander ThompsonDepartment of Stem Cells, Tissue Engineering and Modelling, Centre for Biomolecular Sciences, University of Nottingham, Nottingham, NG7 2RD, UK.ORCID 0000-0002-9315-5321
James G W SmithFaculty of Medicine and Health Sciences, Norwich Medical School, University of East Anglia, Norwich Research Park, Norwich, NR4 7UQ, UK.
Chris DenningDepartment of Stem Cells, Tissue Engineering and Modelling, Centre for Biomolecular Sciences, University of Nottingham, Nottingham, NG7 2RD, UK.
University of Nottingham · GBUniversity of East Anglia · GB

Funding

British Heart Foundation SP/15/9/31605National Centre for the Replacement, Refinement and Reduction of Animals in Research NC/S001808/1
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

CRISPR-Cas SystemsGene SilencingGene TargetingGenetic LociInduced Pluripotent Stem CellsTransgenesCells, CulturedGene ExpressionGene Knock-In TechniquesGenes, ReporterHumansMyocytes, CardiacAAVS1 safe harbourgene targetingHuman induced pluripotent stem cells; CRISPR/Cas9silencingstem-cell derived cardiomyocytesstem-cell derived haematopoietic cells

Identifiers

PMID32789000
PMCPMC7401084
OpenAlexW2962360902

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.